This inventor holds 1 USPTO granted patent. Top assignees: Educational Foundation Kyushu Bunka Gakuen, Kaneka Corporation, National University Corporation Kumamoto University. Active years: 2026.
Company Filing History:
1 out of 2 
1 out of 1,762 
1 out of 9 Years Active: 2026
Title: Hiroaki Matsushita: Innovator in Transthyretin Amyloidosis Treatment
Introduction
Hiroaki Matsushita is a notable inventor based in Sasebo, Japan. He has made significant contributions to the field of medicine, particularly in the treatment of transthyretin amyloidosis. His innovative work has led to the development of a unique stabilizing agent that has the potential to improve patient outcomes.
Latest Patents
Matsushita holds a patent for a transthyretin tetramer stabilizing agent, which serves as a preventing agent or progression suppressing agent for transthyretin amyloidosis. This invention includes glabridin, glabrene, and glabrol as key components. The patent emphasizes the importance of these compounds in stabilizing the transthyretin tetramer, thereby offering a promising approach to managing this condition.
Career Highlights
Throughout his career, Matsushita has worked with reputable organizations, including Kaneka Corporation and the Educational Foundation Kyushu Bunka Gakuen. His experience in these institutions has allowed him to refine his research and contribute to advancements in medical science.
Collaborations
Matsushita has collaborated with notable colleagues, including Jinko Sawashita and Yukio Ando. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Hiroaki Matsushita's contributions to the field of transthyretin amyloidosis treatment highlight his role as an influential inventor. His patent for a transthyretin tetramer stabilizing agent represents a significant advancement in medical research. The impact of his work continues to resonate within the scientific community.